Ascendis Pharma A/S stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Ascendis Pharma A/S stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Ascendis Pharma A/S do? Business model and key facts
Get the full picture of Ascendis Pharma A/S: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 1189
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Stocks related to Ascendis Pharma A/S
Selected based on industry alignment and relative market positioning.
Events and news impacting Ascendis Pharma A/S stock
Earnings, coporate decisions and industry developments that can affect the share price.
Ascendis Pharma A/S fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
